Source: Υπουργείο Υγείας (CY) Revision Year: 2014 Publisher: CODAL-SYNTO Ltd, 33 Theklas Lysioti Street, 3030, Limassol, Cyprus
Pharmacotherapeutic group: Dopamine agonists
ATC code: N04BC01
Bromocriptine is a dopaminergic receptor stimulant or dopamine agonist. The pharmacological action is shown in both normal individuals and in individuals with hyperprolactinaemic states by inhibition of prolactin secretion by the pituitary gland. A lowering of elevated circulating growth hormone levels also results in many acromegalic patients.
In some cases there is evidence, from radiology, to indicate regression of tumours in patients with prolactin secreting adenomas.
In idiopathic Parkinson’s disease, characterised by a specific nigro-striatal dopamine deficiency, bromocriptine is also effective, this is due to its dopaminergic activity.
About 30% of an oral dose is absorbed, and peak plasma levels are reached in about one hour. The elimination half life is about 50 hours. It is extensively protein bound, about 90%-96%.
It undergoes extensive hepatic metabolism, and the main excretion route is in the faeces. There is some renal excretion.
No further relevant information for the prescriber not presented elsewhere in the SmPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
